{"slug":"pt-141","verification":{"valid":true,"entries":39,"head":"9690d2d46d6145208782e2b06ba6880d23267ab99df5335415f822de25675d9f"},"energy":{"passes":39,"tokens_in":3159,"tokens_out":395,"tokens_total":3554,"cost_usd":0,"models":{"grok/grok-4.3":1,"grok-4.3":22,"system/audit-repair":11,"kimi/moonshot-v1-8k":1,"repair":1,"fill-slots":2,"owner":1},"head":"9690d2d46d6145208782e2b06ba6880d23267ab99df5335415f822de25675d9f"},"provenance":[{"ts":"2026-06-29T08:32:57.416Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: PT-141: Brain-Level Arousal\n\nGeneral evidence-graded intro for PT-141: Brain-Level Arousal. Data-first peptide definition article.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"pt-141-brain-level-arousal\",\n  \"title\": \"PT-141: Brain-Level Arousal\",\n  \"body\": \"## PT-141 Definition and Mechanism\\n\\nPT-141 (bremelanotide) is a synthetic melanocortin receptor agonist that activates central nervous system pathways for sexual arousal signaling. [human|mechanistic]\\n\\n## Human Clinical Data\\n\\nIn two identical phase 3 randomized double-blind placebo-controlled trials (RECONNECT), subcutaneous bremelanotide 1.75 mg as needed produced statistically significant increases in Female Sexual Function Index-desire domain scores and reductions in Female Sexual Distress Scale scores versus placebo in premenopausal women with hypoactive sexual desire disorder. [human]\\n\\nBremelanotide received FDA approval in 2019 as Vyleesi for acquired generalized hypoactive sexual desire disorder in premenopausal women. [human]\\n\\n## Preclinical Context\\n\\nAnimal studies indicate melanocortin receptor activation in hypothalamic regions linked to sexual behavior. [preclinical]\\n\\n## Evidence Summary\\n\\nNo human data on long-term use beyond 52-week open-label extensions in the provided trials. User reports exist outside regulated studies but are not graded here.\",\n  \"register\": \"source_ledger\",\n  \"claims\": [\n    {\n      \"id\": \"c1\",\n      \"text\": \"PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist that activates central nervous system pathways for sexual arousal signaling.\",\n      \"section\": \"PT-141 Definition and Mechanism\",\n      \"tier\": \"mechanistic\",\n      \"source_ids\": [\"s1\"],\n      \"source_status\": \"sourced\",\n      \"why_material\": \"Core mechanism definition matching provided peptide entry.\"\n    },\n    {\n      \"id\": \"c2\",\n      \"text\": \"In two identical phase 3 randomized double-blind placebo-controlled trials (RECONNECT), subcutaneous bremelanotide 1.75 mg as needed produced statistically significant increases in Female Sexual Function Index-desire domain scores and reductions in Female Sexual Distress Scale scores versus placebo in premen","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"d9383d565a5188e7170d0617e0563387920ccf1862adde50a0b4432dd89ec203"},{"ts":"2026-06-29T09:46:05.824Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d9383d565a5188e7170d0617e0563387920ccf1862adde50a0b4432dd89ec203","hash":"e4f4261762cc07e0698993ef9f7a7b03b2373dff6de515121c7a5f26f6da9ca1"},{"ts":"2026-06-29T09:46:24.056Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"9 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e4f4261762cc07e0698993ef9f7a7b03b2373dff6de515121c7a5f26f6da9ca1","hash":"b10f9a82bc7e666d0fc023025f5302a623d7f9e3fd28d3c1b21faca913c77e70"},{"ts":"2026-06-29T09:46:42.017Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b10f9a82bc7e666d0fc023025f5302a623d7f9e3fd28d3c1b21faca913c77e70","hash":"9cd819467fab6e8ca130bad03fc64ec5e8c504fb8dc56dbc3941f7e80ece0439"},{"ts":"2026-06-29T09:46:59.840Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9cd819467fab6e8ca130bad03fc64ec5e8c504fb8dc56dbc3941f7e80ece0439","hash":"902545323190b552d006219a4b1a494c81517d0ee2388aaf4a9dd084925ba99f"},{"ts":"2026-06-29T09:48:07.341Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"902545323190b552d006219a4b1a494c81517d0ee2388aaf4a9dd084925ba99f","hash":"8cf534f9ecaeccb44811afe81f52b8a808f6099cfbee508f7d1b7fc011d97f8c"},{"ts":"2026-06-29T09:48:23.788Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8cf534f9ecaeccb44811afe81f52b8a808f6099cfbee508f7d1b7fc011d97f8c","hash":"e30ea642f6112dbe0346e2a9f0c78c3101a63c4e74e0d719128ea9a51a0039a8"},{"ts":"2026-06-29T09:48:42.342Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e30ea642f6112dbe0346e2a9f0c78c3101a63c4e74e0d719128ea9a51a0039a8","hash":"80fe7be9775e4f73fac26f3b69dcb857cb86c35c504f8ed8390af0d7af3a928a"},{"ts":"2026-06-29T09:48:56.066Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"80fe7be9775e4f73fac26f3b69dcb857cb86c35c504f8ed8390af0d7af3a928a","hash":"e6cdef38e2da174d290fef4d9bc61d630eea5c91b4f39f11a14c86ba3852fe9a"},{"ts":"2026-06-29T09:50:08.514Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e6cdef38e2da174d290fef4d9bc61d630eea5c91b4f39f11a14c86ba3852fe9a","hash":"b7690d167a54aa15212d9d4bc3177ec8a9b70c81cd585e7f44fff74e5df0da87"},{"ts":"2026-06-29T09:50:28.395Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b7690d167a54aa15212d9d4bc3177ec8a9b70c81cd585e7f44fff74e5df0da87","hash":"8feae60791a0f0b3cbbbcd5ed84272171f71873f9de96bad8897ae3e1756f58c"},{"ts":"2026-06-29T09:50:45.656Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8feae60791a0f0b3cbbbcd5ed84272171f71873f9de96bad8897ae3e1756f58c","hash":"d2e169b4ee7074f35b089a7b41dbe7c00ef5c49528b15215450f2b1a60cb5756"},{"ts":"2026-06-29T12:47:29.743Z","model":"system/audit-repair","action":"repair","prompt":"","input":"pt-141","response":"{\"materialized\":0,\"before\":[\"4 claims missing posted_by\",\"59 orphan sources (no claim link)\",\"missing constitution slots: what_it_is, who_claims_what, what_is_known, what_is_unknown, limitations, disclaimer\"],\"after\":[\"59 orphan sources (no claim link)\",\"missing constitution slots: what_it_is, who_claims_what, what_is_known, what_is_unknown, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d2e169b4ee7074f35b089a7b41dbe7c00ef5c49528b15215450f2b1a60cb5756","hash":"b3fe0de9f174dba99ecbbb3ca7ab0724d34a29f37f56172c290371fbdf4a1e22"},{"ts":"2026-06-29T12:47:30.362Z","model":"system/audit-repair","action":"claim","prompt":"","input":"pt-141 c5","response":"PT-141: Brain-Level Arousal is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b3fe0de9f174dba99ecbbb3ca7ab0724d34a29f37f56172c290371fbdf4a1e22","hash":"1c6b834cae4058f7430b33a8084a3491b7592228395f5587fa53ee08d313103c"},{"ts":"2026-06-29T12:47:30.431Z","model":"system/audit-repair","action":"claim","prompt":"","input":"pt-141 c6","response":"Per this ledger on PT-141: Brain-Level Arousal: 31 scientific and 30 anecdotal sources are catalogued; 2 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1c6b834cae4058f7430b33a8084a3491b7592228395f5587fa53ee08d313103c","hash":"11ea6bfe45703b741404f64f7e76fd5dc8d2ff13bab2f62df869a11493d5937f"},{"ts":"2026-06-29T12:47:30.633Z","model":"system/audit-repair","action":"claim","prompt":"","input":"pt-141 c7","response":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","tokens_in":0,"tokens_out":0,"cost":0,"prev":"11ea6bfe45703b741404f64f7e76fd5dc8d2ff13bab2f62df869a11493d5937f","hash":"b20ffffe7de5fde6fa8a972d23035bbc6f68eea12adb661ad6a716536af691e9"},{"ts":"2026-06-29T12:47:30.706Z","model":"system/audit-repair","action":"claim","prompt":"","input":"pt-141 c8","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b20ffffe7de5fde6fa8a972d23035bbc6f68eea12adb661ad6a716536af691e9","hash":"d2bb0e289e56e2f0ca86f41a003793b7654143dc4859ea8b449e5f5e4af0e351"},{"ts":"2026-06-29T12:47:30.809Z","model":"system/audit-repair","action":"claim","prompt":"","input":"pt-141 c9","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d2bb0e289e56e2f0ca86f41a003793b7654143dc4859ea8b449e5f5e4af0e351","hash":"1acfb76d7acb46b4a19c6561bbc052031048653b35dab43a2262969ebf6490df"},{"ts":"2026-06-29T12:47:31.510Z","model":"system/audit-repair","action":"repair","prompt":"","input":"pt-141","response":"{\"materialized\":0,\"before\":[\"59 orphan sources (no claim link)\",\"missing constitution slots: who_claims_what\"],\"after\":[\"59 orphan sources (no claim link)\",\"missing constitution slots: who_claims_what\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1acfb76d7acb46b4a19c6561bbc052031048653b35dab43a2262969ebf6490df","hash":"e4801ea955b3dd584bb39c62df464d11c59f2d5cfef4370ae33131642a1de246"},{"ts":"2026-06-29T12:50:42.934Z","model":"system/audit-repair","action":"repair","prompt":"","input":"pt-141","response":"{\"materialized\":59,\"before\":[\"59 orphan sources (no claim link)\",\"missing constitution slots: who_claims_what\"],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e4801ea955b3dd584bb39c62df464d11c59f2d5cfef4370ae33131642a1de246","hash":"bb44c7ca4989e6a69ed8ceb9a5d6395550005dd8307416d50ff278dec8ff51e2"},{"ts":"2026-06-29T12:50:44.959Z","model":"system/audit-repair","action":"repair","prompt":"","input":"pt-141","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"bb44c7ca4989e6a69ed8ceb9a5d6395550005dd8307416d50ff278dec8ff51e2","hash":"c55e3aa6253fdf0e34dfbaae8b0a95c141712ead4b45f63c49d8072e9c20b1fe"},{"ts":"2026-06-29T13:22:33.834Z","model":"system/audit-repair","action":"repair","prompt":"","input":"pt-141","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c55e3aa6253fdf0e34dfbaae8b0a95c141712ead4b45f63c49d8072e9c20b1fe","hash":"0f71d24e885680921ffdd55785df50b6681b52af364b1dccd6030248edd0cb74"},{"ts":"2026-06-29T13:22:35.116Z","model":"system/audit-repair","action":"repair","prompt":"","input":"pt-141","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0f71d24e885680921ffdd55785df50b6681b52af364b1dccd6030248edd0cb74","hash":"5483601255035f262697e1457a2756c84a838075661b4b713fba4fdcbf0b8f14"},{"ts":"2026-06-29T13:53:44.331Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"pt-141","response":"I am adding explicit gaps regarding what is unknown and naming who claims what from anecdotes that are missing, as per the instructions.","tokens_in":3159,"tokens_out":395,"cost":0,"prev":"5483601255035f262697e1457a2756c84a838075661b4b713fba4fdcbf0b8f14","hash":"b8a56c5070ffea28dcd55e51d61a7e7b9f0bfefadac5187d7bcc11077719ad8e"},{"ts":"2026-06-29T15:32:20.112Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b8a56c5070ffea28dcd55e51d61a7e7b9f0bfefadac5187d7bcc11077719ad8e","hash":"8f048ab99b062922141fbcb87caa24be0a31304852cac268c32a49117a04539c"},{"ts":"2026-06-29T15:32:59.010Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8f048ab99b062922141fbcb87caa24be0a31304852cac268c32a49117a04539c","hash":"bc3e452c8d33d6e835e5c7ffe5190c3f4367376d8b206fa93837d9e15434c69a"},{"ts":"2026-06-29T15:33:26.253Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"bc3e452c8d33d6e835e5c7ffe5190c3f4367376d8b206fa93837d9e15434c69a","hash":"aaf78456a66faaaa49b71e4678a9a41a438c112f1fad530f4af70ab9f12fe5c8"},{"ts":"2026-06-29T15:34:19.763Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"aaf78456a66faaaa49b71e4678a9a41a438c112f1fad530f4af70ab9f12fe5c8","hash":"89d2f1843beade3c279b1f37b714ccd0d8e5f4af5187b93421ceb9d9b640248f"},{"ts":"2026-06-29T15:34:57.725Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"89d2f1843beade3c279b1f37b714ccd0d8e5f4af5187b93421ceb9d9b640248f","hash":"e688c7010c68db99022bfb95dde61b678d450c06329ee24930822ef4f7f95930"},{"ts":"2026-06-29T17:34:22.942Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e688c7010c68db99022bfb95dde61b678d450c06329ee24930822ef4f7f95930","hash":"78872614daf9f37c8fcef8a28b5b5877b76e6f291292a93d29d9ed1b01e188e4"},{"ts":"2026-06-29T17:34:47.904Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"78872614daf9f37c8fcef8a28b5b5877b76e6f291292a93d29d9ed1b01e188e4","hash":"87c85dfdc6d3aae4b1de2a33b491dc6b3de71479b94dc9ce756c3b5cf15935e0"},{"ts":"2026-06-29T17:35:27.587Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"87c85dfdc6d3aae4b1de2a33b491dc6b3de71479b94dc9ce756c3b5cf15935e0","hash":"6c5360b7326d6c848a31c1b6f51386f6712cfe6fd171a2b15be8be59879bc53e"},{"ts":"2026-06-29T17:36:24.611Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6c5360b7326d6c848a31c1b6f51386f6712cfe6fd171a2b15be8be59879bc53e","hash":"3bda9cbaf0ac985f6d579c2f619de88adff57cd726a7e8617f7114f66d396e52"},{"ts":"2026-06-29T17:36:52.690Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"3bda9cbaf0ac985f6d579c2f619de88adff57cd726a7e8617f7114f66d396e52","hash":"e0390563902c4e03e634830c3d096becdb77576195f1d59faf74258ecc6bf7d2"},{"ts":"2026-06-29T17:37:20.374Z","model":"grok-4.3","action":"sources","prompt":"","input":"pt-141","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e0390563902c4e03e634830c3d096becdb77576195f1d59faf74258ecc6bf7d2","hash":"16c30a01ab9ed6b7e6c50673ac51b785b482a41cfec33527998b3f8bba924b72"},{"ts":"2026-06-29T19:26:04.123Z","model":"repair","action":"repair","prompt":"","input":"pt-141","response":"{\"materialized\":0,\"before\":[],\"after\":[],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":17}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"16c30a01ab9ed6b7e6c50673ac51b785b482a41cfec33527998b3f8bba924b72","hash":"f94a8b101c385c296b6b00f500bb198aa9f251e3864f2189b18c92043e6bec6c"},{"ts":"2026-06-29T20:40:03.367Z","model":"fill-slots","action":"claim","prompt":"","input":"pt-141 c110","response":"PT-141: Brain-Level Arousal is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f94a8b101c385c296b6b00f500bb198aa9f251e3864f2189b18c92043e6bec6c","hash":"c7ced19669d644d200a55817b582b31a2848bac684789fc3fc1e746541adcfb1"},{"ts":"2026-06-29T20:40:05.817Z","model":"fill-slots","action":"claim","prompt":"","input":"pt-141 c111","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c7ced19669d644d200a55817b582b31a2848bac684789fc3fc1e746541adcfb1","hash":"83a93d959a206686c50dbd6e1cf0dfd527cf6bd77d53cc3fe0c0b95df6e8bef9"},{"ts":"2026-07-17T02:41:03.114Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141","response":"9 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"83a93d959a206686c50dbd6e1cf0dfd527cf6bd77d53cc3fe0c0b95df6e8bef9","hash":"9690d2d46d6145208782e2b06ba6880d23267ab99df5335415f822de25675d9f"}]}